HomeCompareACCD vs JNJ

ACCD vs JNJ: Dividend Comparison 2026

ACCD yields 28.49% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACCD wins by $90.8K in total portfolio value
10 years
ACCD
ACCD
● Live price
28.49%
Share price
$7.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$121.3K
Annual income
$15,341.97
Full ACCD calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — ACCD vs JNJ

📍 ACCD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACCDJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACCD + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACCD pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACCD
Annual income on $10K today (after 15% tax)
$2,421.65/yr
After 10yr DRIP, annual income (after tax)
$13,040.67/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, ACCD beats the other by $9,003.28/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACCD + JNJ for your $10,000?

ACCD: 50%JNJ: 50%
100% JNJ50/50100% ACCD
Portfolio after 10yr
$75.9K
Annual income
$10,045.93/yr
Blended yield
13.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ACCD
Analyst Ratings
7
Buy
13
Hold
Consensus: Hold
Price Target
$13.97
+99.0% upside vs current
Range: $5.00 — $52.00
Altman Z
-1.1
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACCD buys
0
JNJ buys
0
No recent congressional trades found for ACCD or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACCDJNJ
Forward yield28.49%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$121.3K$30.5K
Annual income after 10y$15,341.97$4,749.88
Total dividends collected$81.1K$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$13.97$228.73

Year-by-year: ACCD vs JNJ ($10,000, DRIP)

YearACCD PortfolioACCD Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$13,549$2,849.00$10,594$274.49+$3.0KACCD
2$18,105$3,607.58$11,294$360.69+$6.8KACCD
3$23,878$4,505.31$12,133$476.91+$11.7KACCD
4$31,102$5,553.08$13,156$635.42+$17.9KACCD
5$40,039$6,760.03$14,432$854.61+$25.6KACCD
6$50,975$8,133.20$16,056$1,162.76+$34.9KACCD
7$64,221$9,677.21$18,175$1,604.53+$46.0KACCD
8$80,110$11,394.16$21,009$2,252.68+$59.1KACCD
9$99,002$13,283.47$24,911$3,229.73+$74.1KACCD
10$121,274$15,341.97$30,458$4,749.88+$90.8KACCD

ACCD vs JNJ: Complete Analysis 2026

ACCDStock

Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.

Full ACCD Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ACCD vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACCD vs SCHDACCD vs JEPIACCD vs OACCD vs KOACCD vs MAINACCD vs ABBVACCD vs MRKACCD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.